Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








ACIP Presentation Slides: June 21-23, 2023 Meeting						Print
																Related Pages
										Note: These files are not yet 508
Slides will be added as they become available.
June 21, 2023
Welcome & Introductions
IntroductionDr. G Lee
Dr. M WhartonRespiratory Syncytial Virus Vaccines – Adult
Introduction [8 pages]Dr. C Kotton
Manufacturer presentation: Pfizer season 2 safety & efficacy; coadministration with influenza vaccine [21 pages]Dr. A Gurtman
Manufacturer presentation: GSK season 2 safety & efficacy; coadministration with influenza vaccine [23 pages]Dr. L Friedland
Updated cost-effectiveness of the Pfizer and GSK vaccines (main CDC model) [34 pages]Dr. D Hutton
Comparison of cost effectiveness results of the main CDC model and each manufacturer model (Pfizer & GSK) [27 pages]Dr. I Ortega Sanchez
Updated EtR (incl. GRADE) for 2 vaccines (Pfizer & GSK) [88 pages]Dr. M Melgar
Clinical considerations for 2 vaccines (Pfizer & GSK) [12 pages]Dr. A BrittonPolio Vaccine
Introduction [2 pages]Dr. O Brooks
Recommendations for Adult Polio Vaccination [75 pages]Dr. S KiddInfluenza Vaccines
Introduction [5 pages]Dr. K Talbot
WG considerations [86 pages]Dr. L Grohskopf
Proposed Recommendations [16 pages]Dr. L GrohskopfJune 22, 2023
Welcome & Introductions
IntroductionDr. G Lee
Dr. M WhartonPneumococcal Vaccines
Introduction [13 pages]Dr. K Poehling
Economic analysis and public health impact of PCV20 use in children [33 pages]Dr. C Stoecker
Comparison of cost-effectiveness analyses on PCV20 use in children [44 pages]Dr. D Ayabina
Summary of WG interpretation on EtR and policy options [77 pages]Dr. M KobayashiDengue Vaccines
Introduction [8 pages]Dr. W Chen
Introduction of policy questions for TAK-003 [8 pages]Dr. A Hernandez
Cost effectiveness analysis and health impacts of routine vaccination with TAK-003 dengue vaccine in Puerto Rico [26 pages]Dr. G Espana
Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico [30 pages]Dr. R Kaul
Partial EtR framework for TAK-003 [65 pages]Dr. J WongChikungunya Vaccine
Introduction [6 pages]Dr. B Bell
Value of chikungunya vaccine to U.S. travelers and providers [30 pages]Ms. N Lindsey
Chikungunya virus infection among laboratory workers [9 pages]Dr. S Hills
Update on large chikungunya outbreak in Paraguay [12 pages]Dr. S Hills
Workgroup plans and timelines [4 pages]Dr. S HillsRespiratory Syncytial Virus Vaccines – Pediatric/Maternal
Introduction [6 pages]Dr. S Long
Economic analysis of RSVpreF in pediatric populations [52 pages]Dr. D Hutton
EtR Pfizer maternal RSV vaccine [130 pages]Dr. K Fleming-Dutra
Economic analysis of combined use of nirsevimab and maternal RSVpreF vaccine [57 pages]Dr. D Hutton
Clinical considerations for RSV maternal vaccine and nirsevimab [11 pages]Dr. J JonesJune 23, 2023
Welcome & Introductions
IntroductionDr. G LeeMpox Vaccine
Introduction [17 pages]Dr. P Sanchez
Updates From the 2022/2023 U.S. Mpox Outbreak: Epidemiology, Vaccine Safety, and Vaccine Effectiveness [35 pages]Dr. F Minhaj
Use of JYNNEOS During Mpox Outbreaks: Clinical guidance [25 pages]Dr. A Rao
Considerations for Long-term Protection Against Mpox [24 pages]Dr. A RaoMeningococcal Vaccines
Introduction [5 pages]Dr. K Poehling
Cost effectiveness analysis [39 pages]Dr. I Ortega-Sanchez
GRADE/EtR; Summary and workgroup considerations [85 pages]Dr. S CrowVaccine Safety
Introduction [7 pages]Dr. T Shimabukuro
The childhood immunization schedule and safety: Studies in the Vaccine Safety Datalink [20 pages]Dr. M Daley
Preliminary evaluation of aluminum content in childhood vaccines and risk of asthma in a Danish nationwide cohort [12 pages]Dr. A HviidCOVID-19 Vaccines
Introduction [8 pages]Dr. M Daley
Updates to COVID-19 epidemiology and vaccine effectiveness [62 pages]Dr. F Havers, Dr. R Galang, Dr. R Link-Gelles
Infection-induced and hybrid immunity [14 pages]Dr. J Jones
Summary and work group considerations [21 pages]Dr. M Wallace
							
					
							Last Reviewed:  June 23, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue